Ocular surface toxicity of depatuxizumab mafoditin (ABT-414): case reports.

Rocha-de-Lossada, Carlos; Linero, Carmen Alba; Ortega, Álvaro Santos; Calvo-de-Mora, Marina Rodríguez; Rachwani, Rahul; Borroni, Davide; Alba, Emilio; Orgaz, Manuel Benavides; Romano, Vito

The purpose of this study is to report the clinical features and outcomes of ocular surface toxicity following depatuxizumab mafoditin (ABT-414) therapy for unresectable glioblastoma. Ocular signs and symptoms of three patients treated with ABT-414 during a phase III trial for glioblastoma multiforme were evaluated. Both eyes of all patients were damaged during the week after the first infusion of the ABT-414 molecule. In all patients, mild-to-moderate keratitis could be ascertained, along with decreased visual acuity and blurred vision, as well as foreign-body sensation and redness. Symptoms and visual acuity improved 4 weeks. In conclusion, ABT-414 therapy may cause transient ocular surface toxicity. The initiation of artificial tears and lubricant ointment was enough to control the ocular surface signs and symptoms. A multidisciplinary approach, complete ophthalmologic monitorization, and elaboration of protocols are required to adequately manage these patients.